TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10215775
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (200 mg once daily for 3 months)
Study: 7759273
Drug: music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: music therapy
Study: 7759273
Drug: music-video therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: music-video therapy
Study: 2186658
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with fentanyl 100 mcg
Study: 29310376
Drug: Fentanyl 25 μg
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 25 μg and morphine 100 μg (FM group)
Study: 29310376
Drug: Morphine 100 μg
Normalized name: morphine sulfate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 μg (M group)
Study: 24986038
Drug: Qsymia (phentermine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qsymia (phentermine 7.5 mg plus topiramate 46.0 mg)
Study: 22087680
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg per kilogram of body weight per day)
Study: 20002061
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g activated charcoal (control)
Study: 20002061
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g activated charcoal
Study: 20002061
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g activated charcoal
Study: 17635578
Drug: Inhaled PACAP38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PACAP38 (cumulative dose of 480 microg)
Study: 17635578
Drug: Inhaled PACAP38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PACAP38
Study: 15240645
Drug: Abacavir (replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (replacement of protease inhibitor)
Study: 11777752
Drug: Intact tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact tablet after high-fat breakfast
Study: 11777752
Drug: Tablet split
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet split into three fragments
Study: 11777752
Drug: Fractional dosing
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional dosing (40 mg in the morning and 20 mg in the evening)
Study: 11777752
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing
Study: 9694707
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cyanocobalamin orally daily for 120 days
Study: 9694707
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cyanocobalamin intramuscularly on days 1, 3, 7, 10, 14, 21, 30, 60, and 90
Study: 8087823
Drug: Isosorbide‐5‐mononitrate (ISMN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (ISMN) 20 mg b.i.d.
Study: 8087823
Drug: Isosorbide‐5‐mononitrate (ISMN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (ISMN) 5 mg b.i.d.
Study: 8087823
Drug: Isosorbide‐5‐mononitrate (ISMN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (ISMN) 10 mg b.i.d.
Study: 28138158
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of low-dose endotoxin (0.8 ng/kg body weight)
Study: 28138158
Drug: Endotoxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin treatment
Study: 12548315
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of virgin olive oil (50 ml)
Study: 12548315
Drug: Sustained doses
Normalized name: Sustain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained doses of virgin olive oil (25 ml/day for one week)
Study: 9477785
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in quality 1 and 2 bone
Study: 9477785
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in quality 3 bone
Study: 9477785
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in quality 4 bone
Study: 9477785
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in the posterior maxilla
Study: 9477785
Drug: Single implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single implants in the anterior maxilla
Study: 9477785
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in other regions
Study: 8463866
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of albendazole (600 mg, 1x)
Study: 8463866
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of albendazole (600 mg, 2x)
Study: 3100707
Drug: Cervical score-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical score-based timing of hCG administration
Study: 3100707
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and ultrasound-based timing of hCG administration
Study: 20422949
Drug: Valacyclovir hydrochloride
Normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir hydrochloride (150 mg/capsule, test preparation)
Study: 20422949
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available original capsule (150 mg/capsule, reference preparation)
Study: 15225193
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg once a day
Study: 15225193
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg once a day
Study: 15225193
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid 500 mg three times a day
Study: 15225193
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg and 15 mg
Study: 9524901
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral doses of dolasetron mesylate
Study: 9524901
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral doses of dolasetron mesylate
Study: 9524901
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral doses of dolasetron mesylate
Study: 9524901
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral doses of dolasetron mesylate
Study: 8591940
Drug: Itraconazole 5
Normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 5 mg/kg od
Study: 8591940
Drug: Itraconazole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 2.5 mg/kg bd
Study: 8591940
Drug: Itraconazole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 2.5 mg/kg od
Study: 2655676
Drug: Japanese BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese BCG vaccine
Study: 2655676
Drug: British BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: British BCG vaccine
Study: 1248096
Drug: Automatic device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic device for metered dose release
Study: 23963355
Drug: BGG492 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 (250 mg)
Study: 10497008
Drug: Nelfinavir (NFV),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir (NFV), d4T, or NFV + d4T for 24 weeks, followed by triple therapy (NFV + reverse transcriptase inhibitors) for an additional 24 weeks
Study: 1918842
Drug: Sucralfate, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 2 g b.i.d. (in smokers)
Study: 1918842
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg twice daily (in smokers)
Study: 6123808
Drug: Terlipressin ('Glypressin')
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin ('Glypressin') 2 mg every 6 hours
Study: 6123808
Drug: Vasopressin 0.4
Normalized name: VASOPRESSIN 0.4 UNIT/ML INJ VIAL 100ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin 0.4 units/min IV infusion
Study: 31626157
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (disease-modifying anti-rheumatic drugs and therapeutic exercises)
Study: 28947723
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin (ASA)
Study: 28947723
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (20 mg rivaroxaban, 10 mg rivaroxaban, 100 mg ASA)
Study: 24912653
Drug: Prophylactic transfusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic transfusion of fresh-frozen plasma (FFP) at a dosage of 12 mL/kg
Study: 22747953
Drug: First-line and
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line and second-line anti-tuberculosis drugs
Study: 21163116
Drug: Ligustrazine plus
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine plus chemotherapy
Study: 16248392
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone levels
Study: 7138720
Drug: high-level extradural
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-level extradural morphine
Study: 7138720
Drug: low-level extradural
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-level extradural morphine
Study: 30119941
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous hydromorphone
Study: 30119941
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous acetaminophen
Study: 18198642
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) - non-steroid anti-inflammatory agents and slow acting medicine
Study: 18198642
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) - basic remedy and syndrome differentiating medication
Study: 15473621
Drug: Levobupivacaine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 2.5 mg mL(‐1) 30 mL with epinephrine 5 microg mL(‐1)
Study: 15473621
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 30 mL with epinephrine 5 microg mL(‐1)
Study: 8451781
Drug: Gentamicin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin loading dose of 3 mg/kg
Study: 8451781
Drug: Gentamicin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin loading dose of 4 mg/kg for younger patients (<= 34 weeks gestational age)
Study: 8451781
Drug: Mean initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mean initial dose delivered was 2.41 mg/kg
Study: 31928690
Drug: Pan-PI3K inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pan-PI3K inhibitors
Study: 22044287
Drug: S-adenosyl-L-methionine (SAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAM) 1.2 g by mouth daily
Study: 19825328
Drug: Film-coated tablets
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablets (2 x 12.5 mg diclofenac-K)
Study: 19825328
Drug: Sugar-coated tablet
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated tablet (1 x 25 mg diclofenac-K)
Study: 15297095
Drug: Protein-rich liquid
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich liquid formula (Fortimel, 200 ml/day, 20 g protein/day)
Study: 15297095
Drug: Protein-rich liquid
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich liquid formula (Fortimel, 200 ml/day, 20 g protein/day) + nandrolone decanoate (Deca-Durabol 25 mg i.m./3 weeks)
Study: 11465652
Drug: Cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5 mg/day)
Study: 8276045
Drug: Cholic acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cholic acid (CA) 10 mg.kg‐1 per day for 3 months
Study: 8276045
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at the same dose after CA therapy
Study: 2880692
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of SMS 201-995 (2 mg) with 75 g of glucose
Study: 29723659
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea herbal consumed daily for 6 weeks
Study: 728894
Drug: FAC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC chemotherapy alone
Study: 8857916
Drug: Cyclic transdermal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic transdermal therapy (17 beta‐estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d for 12 days per cycle)
Study: 8857916
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral therapy (17 beta‐estradiol 2 mg/d + norethisterone acetate 1 mg/d for 12 months)
Study: 6380067
Drug: Isoniazid and
Normalized name: Isoniazid and rifampin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid and ethambutol, thrice weekly for 18 months
Study: 21147743
Drug: No antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiepileptic treatment
Study: 17955358
Drug: L-carnitine 5
Normalized name: L-Carnitine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 5 g IV bolus followed by 10 g/day IV infusion for 3 days
Study: 15681529
Drug: Prinomastat 15
Normalized name: Prinomastat
DrugBank: Prinomastat (DB05100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prinomastat 15 mg plus gemcitabine-cisplatin chemotherapy
Study: 15681529
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus gemcitabine-cisplatin chemotherapy
Study: 11907945
Drug: Tibolone (Livial)
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (Livial) daily
Study: 11907945
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE, Premarin) plus sequential medroxyprogesterone acetate (MPA, Prodafem)
Study: 1093458
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg meperidine
Study: 25847016
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg, two times a day for 3 days
Study: 25847016
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg, two times a day for 3 days
Study: 22491708
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion analgesia (intermittent bolus intra-articular injection of ropivacaine, dexamethasone, and isepamicin until postoperative 48 hours)
Study: 22491708
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion analgesia
Study: 10902994
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg iron + either 1171 or 209 kJ
Study: 8881899
Drug: Cyclosporin 5
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 5 mg/kg per day decreasing to 3 mg/kg per day (Group A)
Study: 8881899
Drug: Cyclosporin 3
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 3 mg/kg per day increasing to 5 mg/kg per day (Group B)
Study: 1328784
Drug: 5000 I.U.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 I.U. heparin administered twice daily
Study: 1328784
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (3000 I.U. anti-Xa) administered daily
Study: 1328784
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (heparin and low molecular weight heparin)
Study: 28916603
Drug: Elamipretide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide (0.05 mg/kg per hour intravenous infusion)
Study: 26333337
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of monovalent influenza A H1N1 vaccine
Study: 20490632
Drug: Twelve-step facilitated
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve-step facilitated (TSF) group treatment
Study: 20490632
Drug: Node-link mapping-enhanced
Normalized name: amylopectin (4,5-dihydroxy-1,3-dimethylimdazolidin-2-one cross linked)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Node-link mapping-enhanced cognitive-behavioral group therapy (CBGT-mapping)
Study: 14552398
Drug: Training sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training sessions with various analogous tasks; specific details on dosage and duration not available.
Study: 14552398
Drug: Positive-capture strategy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive-capture strategy; specific details on dosage and duration not available.
Study: 10944130
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFNalpha2a plus 13‐CRA)
Study: 8823826
Drug: Steroid-eluting electrodes
Normalized name: ELECTRODE ELECTROLYTE SPRAY,TOP,PMT#CS4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting electrodes
Study: 8823826
Drug: Non-steroid electrodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid electrodes
Study: 1485705
Drug: Solcoderm topical
Normalized name: TITANIUM DIOXIDE 60 mg in 1 mL / ZINC OXIDE 60 mg in 1 mL TOPICAL CREAM [ONCODERM Rx Mineral Sunscreen SPF-30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoderm topical application
Study: 1485705
Drug: Usual conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual conservative treatment
Study: 3922732
Drug: Amiodarone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (7.5 mg/kg intravenously over 5 minutes followed by oral administration for 3 weeks)
Study: 3922732
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (0.8 mg sublingually)
Study: 31384906
Drug: Er, Cr:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er, Cr: YSGG water laser treatment
Study: 22445107
Drug: Steroid-antiviral combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-antiviral combination therapy
Study: 22445107
Drug: Steroid-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-only treatment
Study: 12162473
Drug: Conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional ibuprofen 200 mg
Study: 12162473
Drug: Ibuprofen arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginate
Study: 12162473
Drug: Conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional ibuprofen
Study: 10682464
Drug: Materna treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Materna treatment (1 tablet daily) in preventive group (n = 96)
Study: 10682464
Drug: Materna treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Materna treatment (1 tablet daily) in treatment group (n = 93)
Study: 10682464
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (0.3 g tid/d) in treatment group (n = 50)
Study: 10682464
Drug: Ferroids (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroids (1 tablet/d) in treatment group (n = 35)
Study: 683275
Drug: Somatostatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (2 mg per day)
Study: 29425226
Drug: Pamphlets and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlets and one poster on influenza vaccine in GPs' waiting rooms (intervention group)
Study: 26258655
Drug: Dexmedetomidine 0.5 μg kg⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg kg⁻¹ i.v. 30 minutes before surgery
Study: 25011949
Drug: 3.1 mg
Normalized name: menthol 3.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.1 mg otelixizumab administered over 8 days
Study: 25011949
Drug: 3.1 mg
Normalized name: menthol 3.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.1 mg otelixizumab
Study: 15891593
Drug: Single-injection gated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection gated SPECT with 99mTc tetrofosmin performed 3 days after primary PCI
Study: 15891593
Drug: Single-injection gated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection gated SPECT with 99mTc tetrofosmin